DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8hl86b/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects.
Companies Involved in Therapeutics Development
- Mesoblast Limited
- Cleveland BioLabs, Inc.
- Compugen Ltd.
- Pluristem Therapeutics Inc.
- Spectrum Pharmaceuticals, Inc.
- TikoMed AB
-
Taiga Biotechnologies, Inc.
Drug Profiles
- Allogeneic MPC For Bone Marrow Transplantation
- melphalan
- TM-400
- PLX-BMP
- CBLB-612
- CBLB-612
- CGEN-15001
- Small Molecule to Inhibit Perforin for Bone Marrow Transplantation
-
Protein for Bone Marrow Transplantation
Companies Mentioned:
- Mesoblast Limited
- Cleveland BioLabs, Inc.
- Compugen Ltd.
- Pluristem Therapeutics Inc.
- Spectrum Pharmaceuticals, Inc.
- TikoMed AB
- Taiga Biotechnologies, Inc.
For more information visit http://www.researchandmarkets.com/research/8hl86b/bone_marrow
